Bronte Naples
Family · Chattanooga, TNNPI 1992291926
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,745 of the $26,362 with a category attached, or 67.3%. Gilead accounts for 90.9% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $9,886, 7.6 times the $1,306 reported in 2021. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $121.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$24K
- AbbVie$685
- Viiv Healthcare Company$305
- Novo Nordisk$288
- AstraZeneca$281
- Janssen Products, LP$252
- plus $593 from 9 others
What the payments were for
- Speaking & faculty fees$17,74567%
- Travel & lodging$3,25912%
- Food & beverage$5,10619%
- Education$2521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 148 | $23,959 |
| AbbVie | 18 | $685 |
| Viiv Healthcare Company | 24 | $305 |
| Novo Nordisk | 6 | $288 |
| AstraZeneca | 4 | $281 |
| Janssen Products, LP | 3 | $252 |
| Johnson & Johnson(2 entities) | 5 | $193 |
| Boston Scientific | 1 | $131 |
| Mylan Specialty L.p. | 1 | $124 |
| Coopersurgical, Inc. | 1 | $42 |
| Theratechnologies Inc. | 2 | $33 |
| Pfizer | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Bayer | 1 | $13 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,362 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 346 | $1,384,044 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 62 | $203,602 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 44 | $188,801 |
| DescovyEmtricitabine/Tenofov Alafenam | 92 | $188,033 |
| TivicayDolutegravir Sodium | 71 | $147,015 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 27 | $126,535 |
| PrezcobixDarunavir/Cobicistat | 39 | $94,315 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 26 | $90,950 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $39,225 |
| MounjaroTirzepatide | 12 | $11,759 |
| FarxigaDapagliflozin Propanediol | 12 | $7,031 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $3,050 |
| ValacyclovirValacyclovir Hcl | 70 | $2,280 |
| Atorvastatin Calcium | 143 | $809 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $23,959 | $1,760,878482 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Dovato | $305 | $389,842147 claims |
| Janssen Products, LPSymtuza | $252 | $126,53527 claims |
| Johnson & JohnsonPrezcobix | $193 | $94,31539 claims |
| Lilly USA, LLCMounjaro | $11 | $11,75912 claims |
| AstraZenecaFarxiga | $281 | $7,03112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Chattanooga
- Jennifer SparksChattanooga$120K
- Marcie BeasleyChattanooga$91K
- Amy RainsChattanooga$55K
- Ernest BrandtChattanooga$21K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.